
Nippon India Pharma Fund Direct Growth
Nippon India Pharma Fund Direct Growth
as on 06 Nov 2026
Nippon India Pharma Fund Direct Growth is a Equity mutual fund scheme launched on 01 Jan 2013. The current NAV stands at ₹646.8090 as of 06 Nov 2026. From the funds total AUM, its top holdings include Sun Pharmaceutical at 13.35%, Lupin at 7.31%, Dr Reddys Laboratories at 6.72%, Cipla at 6.16%, Divis Laboratories at 5.80%
Scheme Overview
- Inception Date : 01 Jan 2013
- AUM : ₹9,166.40 Cr
- 5Y Returns (CAGR) : 14.82%
- Expense Ratio : 1.00%
- Min. SIP : ₹100
- Min. Lumpsum : ₹5,000
Returns Calculator
basis annualised returns
Investment Type
SIP Amount
Investment Period
5Y
₹ 32.73 L
3.50%
₹ 36.98 L
8.00%
₹ 44.61 L
14.82%
Total Investment
₹ 30,00,000
Returns
₹ 14,61,441 (14.82%)
Maturity Value
₹ 44,61,441
Disclaimer: Fixed deposits offer guaranteed returns. Mutual fund investments carry market risks; read all scheme-related documents carefully. Past performance does not guarantee future returns.
Direct vs Regular Returns
Sorry, No Data Available at this Moment!
Returns vs Category
Sorry, No Data Available at this Moment!
*The above returns are absolute
Returns Vs Nifty 50
Historical Returns
Sorry, No Data Available at this Moment!
Start SIP with as Low as ₹100.
Historical NAV
Sorry, No Data Available at this Moment!
Asset Allocation
AUM
₹ 9,166.40 Cr
Cash Holding
-
Equity
-
Cash
-
Debt
-
Other
-
Asset Allocation
AUM
₹9,166.40 Cr
Cash Holding
-
Equity
-
Cash
-
Debt
-
Other
-
Sector Holdings
as of 31 May 2026
| Sectors | Allocation | Weightage | Value (in Cr.) |
|---|---|---|---|
| Healthcare | 97.92% | ||
| Other | 2.08% |
Stock Holdings
as of 31 May 2026
| Name | Allocation | Weightage |
|---|---|---|
![]() S Sun Pharmaceutical | 13.35% | |
![]() L Lupin | 7.31% | |
![]() D Dr Reddys Laboratories | 6.72% | |
![]() C Cipla | 6.16% | |
![]() D Divis Laboratories | 5.80% | |
![]() A Apollo Hospitals | 5.20% | |
![]() M Mankind Pharma | 3.94% | |
![]() M Medplus Health Services | 3.68% | |
![]() S Sai Life Sciences | 3.43% | |
![]() A Ajanta Pharma | 3.21% | |
![]() V Vijaya Diagnostic Centre | 3.21% | |
![]() M Max Healthcare Institute | 2.97% | |
![]() T Thyrocare Technologies | 2.56% | |
![]() I IPCA Laboratories | 2.41% | |
![]() G GlaxoSmithKline Pharmaceuticals | 2.34% | |
![]() A Aurobindo Pharma | 2.32% | |
![]() A Abbott | 2.31% | |
![]() T Triparty Repo | 2.16% | |
![]() G Gland Pharma | 2.09% | |
![]() A Alkem Laboratories | 2.06% | |
![]() D Dr. Lal Path Labs | 1.90% | |
![]() N Narayana Hrudayalaya | 1.81% | |
![]() S Syngene International | 1.79% | |
![]() P Pfizer | 1.69% | |
![]() E Emcure Pharmaceuticals | 1.47% | |
![]() S Suraksha Diagnostic | 1.29% | |
![]() F Fortis Healthcare | 1.19% | |
S Sanofi Consumer Healthcare | 1.14% | |
![]() A Anthem Biosciences | 0.93% | |
![]() A Akums Drugs & Pharma | 0.92% | |
![]() S Sanofi | 0.83% | |
![]() B Biocon | 0.73% | |
![]() A AstraZeneca Pharma | 0.63% | |
![]() I Indoco Remedies | 0.45% | |
![]() C Concord Biotech | 0.14% | |
![]() N Net Current Assets | 0.08% | |
![]() C Cash Margin - Ccil | 0.00% |
Fund Comparison
Fund Details
52W High NAV
₹ 653.6135
Min. SIP Amount
₹ 100.00
Min. Lumpsum Amount
₹ 5,000.00
AUM (in Cr.)
₹ 9,166.40
Expense Ratio
1.00%
Lock-in Period
No Lock in Period
52W Low NAV
₹ 539.2707
Inception Date
01 Jan 2013
Fund Age
13 Yrs
Benchmark
BSE Healthcare TRI
Scheme Type
Open Ended
Stamp Duty
0.005% (from July 1st 2020)
Exit Load
- Exit load of 1% if redeemed within 1 month.
Tax Implication
- If you redeem within 1 year, STCG are taxed at 20%; If you redeem after 1 year, and returns exceed ₹1.25 Lakhs in a financial year, LTCG are taxed at 12.5%
Fund Managers
| Name | Qualification |
|---|---|
| Sailesh Raj Bhan | MBA (Finance), CFA. |
| Divya Dutt Sharma | Bachelor of Commerce, MSC Banking & Finance |
| Lokesh Maru | Bachelor of Technology, CFA, FRM |
Fund Objective
The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.
Risk-O-Meter
Investors understand that their principal will be at
Very High Risk
Risk Scale
Low
Moderately Low
Moderate
Moderately High
High
Very High
AMC Information
Nippon India Mutual Fund
No. of Schemes
70
Total AUM
₹ 5,21,584.04 Cr
Contact Details
4th Floor, Tower A, Peninsula Busines-s Park, Ganapatrao Kadam MargLower Parel (W), Mumbai - 400013.
Contact Details
4th Floor, Tower A, Peninsula Busines-s Park, Ganapatrao Kadam MargLower Parel (W), Mumbai - 400013.
FAQs
When was Nippon India Pharma Fund launched?
What is the current NAV of Nippon India Pharma Fund?
What is the AUM of Nippon India Pharma Fund?
What is the rate of return of Nippon India Pharma Fund?
- In the past 1Y: 12.68%
- In the past 3Y: 19.00%
- In the past 5Y: 14.82%
What is the expense ratio of Nippon India Pharma Fund?
What is exit load of Nippon India Pharma Fund?
What is the portfolio of Nippon India Pharma Fund?
- Sun Pharmaceutical: 13.35%
- Lupin: 7.31%
- Dr Reddys Laboratories: 6.72%
- Cipla: 6.16%
- Divis Laboratories: 5.80%
Top 3 sectoral holdings include:
- Healthcare: 97.92%
- Others: 2.24%
How risky is investing in Nippon India Pharma Fund?
Who is the fund manager Nippon India Pharma Fund?
What is the minimum investment required in Nippon India Pharma Fund?
How to invest in Nippon India Pharma Fund directly?
- Open Demat Account on Dhan if you don't have one.
- Analyze the fund performance.
- Invest via SIP or Lumpsum.

Invest in
Pay 0% Commission!
+91
Or Scan the QR Code to download the Dhan App




































